Tagged with Oncology

China This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities were made to sit up and listen following the box office success of a low budget film called “Dying to…

Spain The managing director of the Spanish affiliate of one of France’s most exciting and ambitious mid-caps speaks out about crafting a commercial powerhouse and efficient launch machine in oncology, and shares the secrets of deftly managing organizational change.    How would you describe Ipsen´s legacy and footprint within the Spanish…

UK Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the affiliate the best performing in the coming years. She also details the strong heritage of Oncology and the affiliate’s exciting…

UK Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as a homegrown British biotech with confidence. Its CEO Andrew Hotchkiss also shares some of the up-coming investigation programmes for Immunocore’s…

UK With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short period of time. Currently active in both the UK and Europe, EUSA is set to further expand internationally, notably in…

Baltics Rauls Velins, Roche’s general manager for Latvia, introduces the company’s longstanding commitment to the Latvian market, Roche’s role in helping facilitate Latvia’s new National Cancer Plan, and the potential for personalized medicine across the Baltics. Could you please start by introducing Roche in Latvia and the strategic significance of the…

Ecuador Antonio Carlos Matos da Silva, general manager of Roche Ecuador explains how his ability to manage by influence has helped him transition smoothly into his first GM position. The Brazilian manager has great ambitions for the Ecuadorian affiliate of the oncology global giant, elaborating on Vision 2020; a plan he…

Canada Taiho Pharmaceutical Co., Ltd. (TPC), Japan, part of Otsuka Holdings, established its Canadian affiliate in 2017. Ross Glover, general manager for Taiho Pharma Canada, has spent the past year tackling the mammoth task of establishing the foundations for the operations, including preparing a new drug for market approval and navigating…

Poland Joanna Drewla, general manager of Servier Poland, discusses Polish healthcare challenges and looks at areas for improvement to create a sustainable balance for market access of innovative treatments. Furthermore, she highlights the strategic importance of Servier in Poland, with the International Center for CEE clinical research and the company’s fifth…

Latvia A social partner for Latvia! This is how Kristine Juckovica, executive director and Karlis Urbans, head of business development describe Rigvir Holding, the Latvian enterprise behind the homonymous virus-based cancer treatment produced by the ECHO-7 virus Can you kick off by introducing the structure of the company to our international…

India Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main trends shaping India’s pharmaceutical industry, while documenting BDR’s eye-catching achievements and areas of expertise, as well as the strategic alliances…

Serbia By reorganizing their management structure, diversifying their offering and presenting an altogether cleaner image, AstraZeneca Serbia has made tremendous progress since its beginnings in the Balkans in the late 1990s. Country Director Ksenija Purkovic discusses the future of the Anglo-Swedish outfit, and how best to navigate a market that is…